Department of Nuclear Medicine, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fushun, Liaoning, China.
Department of Endocrinology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fushun, Liaoning, China.
Pharm Biol. 2020 Dec;58(1):944-949. doi: 10.1080/13880209.2020.1817951.
L. (Solanaceae) polysaccharides (LBPs) are important active constituents that have demonstrated kidney protection.
This study investigated the effect of LBPs on hyperuricaemia and explored the underlying mechanism in mice.
Thirty-six C57BL/6 mice were randomly divided into the control group, hyperuricaemia group, allopurinol group (5 mg/kg) and three LBP groups (n = 6). The LBP groups were treated orally with LBPs at 50, 100 and 200 mg/kg body weight for 7 days. We examined the levels of serum uric acid (S) and urinary uric acid (U), as well as xanthine oxidase (XOD) activities. mRNA and protein were quantified by quantitative real-time PCR and Western blotting, respectively.
LBPs treatment (100 and 200 mg/kg) significantly reduced the S levels to 4.83 and 4.48 mg/dL, and markedly elevated the U levels to 4.68 and 5.18 mg/dL ( < 0.05), respectively, while significantly increased the mRNA and protein expression levels of renal organic anti-transporter 1 (OAT1) and organic anti-transporter 3 (OAT3), and markedly decreased the levels of glucose transporter 9 (GLUT9) ( < 0.05). Additionally, the serum XOD activities were reduced to 31.5 and 31.1 mU/mL, and the liver XOD activities were reduced to 80.6 and 75.6 mU/mL after treatment with 100 and 200 mg/kg LBPs ( < 0.01), respectively.
This study demonstrated the potential role of LBPs in reducing the uric acid level in hyperuricemic mice. A border study population should be evaluated. These results are valuable for the development of new anti-hyperuricaemia agents from LBPs.
龙葵（茄科）多糖（LBPs）是具有肾脏保护作用的重要活性成分。
本研究探讨 LBPs 对高尿酸血症的影响及其在小鼠体内的作用机制。
将 36 只 C57BL/6 小鼠随机分为对照组、高尿酸血症组、别嘌醇组（5mg/kg）和 3 个 LBPs 组（n=6）。LBPs 组分别以 50、100 和 200mg/kg 体重灌胃给药 7 天。检测血清尿酸（S）和尿尿酸（U）水平以及黄嘌呤氧化酶（XOD）活性。采用实时定量 PCR 和 Western blot 分别定量检测 mRNA 和蛋白。
LBPs 治疗（100 和 200mg/kg）可显著降低 S 水平至 4.83 和 4.48mg/dL，并显著升高 U 水平至 4.68 和 5.18mg/dL（<0.05），同时显著上调肾脏有机阴离子转运体 1（OAT1）和有机阴离子转运体 3（OAT3）的 mRNA 和蛋白表达水平，并显著下调葡萄糖转运蛋白 9（GLUT9）的水平（<0.05）。此外，100 和 200mg/kg LBPs 治疗后血清 XOD 活性分别降低至 31.5 和 31.1mU/mL，肝 XOD 活性分别降低至 80.6 和 75.6mU/mL（<0.01）。
本研究表明 LBPs 具有降低高尿酸血症小鼠血尿酸水平的潜力。应评估边界研究人群。这些结果对于从 LBPs 开发新型抗高尿酸血症药物具有重要价值。
